CSL (ASX:CSL) expects fiscal 2027 revenue to be flat while making a return to profit growth after fiscal 2026 results beat estimates amid restructuring.
The biotechnology company reported $6.43 in underlying NPATA earnings per share for fiscal 2026, compared with $6.65 a year ago and beating analysts' estimates surveyed by FactSet of $6.27.
Revenue for the year was $15.8 billion, beating the estimate of $15.38 billion from analysts polled by FactSet, while paying restructuring costs of $799 million.
The biotechnology firm attributed the results to "strong fundamentals" of the plasma industry and said momentum is building behind its newer therapy products.
Looking ahead, CSL expects fiscal 2027 revenue to be flat with 5% growth in its underlying net profit after tax.
"CSL is positioned for a return to sustainable growth, supported by solid plasma market fundamentals, a simplified business and targeted investment in our commercial capabilities and development programs," said Interim Chief Executive Officer Gordon Naylor.
Jefferies, commenting on the company's Behring business, said productivity gains were insufficient to offset lower revenue against the division's high fixed-cost base as the segment's gross margin declined 70 basis points to 49.6%.



